Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
First Trust Nasdaq Pharmaceuticals ETF (FTXH) belongs to the US Health Care segment. The Health Care Select Sector SPDR Premium Income Fund (XLVI) is part of the Options Strategies segment. Both ETFs have the same top 3 sector exposures: and Health Care. FTXH is more expensive with a Total Expense Ratio (TER) of 0.6%, versus 0.35% for XLVI. FTXH is up 5.06% year-to-date (YTD) with +$7M in YTD flows. XLVI performs worse with 0.43% YTD performance, and +$2M in YTD flows. Run a side-by-side ETF comparison of FTXH and XLVI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | FTXH XLVI | -0.60%-0.34% | +7.47%+2.91% | +5.06%+0.43% | +22.29%n/a | +43.33%n/a | +43.47%n/a |
| Flows | FTXH XLVI | +$5M+$788K | +$9M+$3M | +$7M+$2M | +$10M- | -$13M- | +$4M- |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | FTXH XLVI | +15.29%+10.28% | +20.64%n/a | +15.87%n/a | +15.67%n/a |
| Max drawdown | FTXH XLVI | -4.33%-3.26% | -17.49%n/a | -19.32%n/a | -19.32%n/a |
| Max drawdown duration | FTXH XLVI | 9d9d | 203dn/a | 393dn/a | 393dn/a |
FTXH | XLVI | |
Last sale 3/11/2026 at 1:30 PM | $34.46 | $25.92 |
| Previous close 03/10/2026 | $34.57 | $25.98 |
| Consolidated volume 03/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
FTXH | XLVI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
FTXH | XLVI | |
|---|---|---|
| Last price | $34.46 | $25.92 |
| 1D performance | -0.33% | -0.23% |
| AuM | $29.41 M | $13.26 M |
| E/R | 0.6% | 0.35% |
FTXH | XLVI | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | First Trust | SPDR |
| Benchmark | NASDAQ US Smart Pharmaceuticals Index | - |
| N° of holdings | 49 | 57 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | September 20, 2016 | July 30, 2025 |
| ESG | No | No |
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Direxion partnered with Compound Insights and Vanda to explore what’s driving the evolution of active trading — and how active traders are using leveraged and inverse funds across equities, single stocks, commodities, and volatility.
